All sponsors

argenx $ARGX

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS29
PHASE 3 / 2-316
RECRUITING11
READOUTS ≤12 MONTHS11
READOUT SLIPPED >6 MO53%

Delay Index: of 19 active trials registered more than a year ago, 10 have moved their primary completion (readout) date by more than 6 months since first registration (median +6.4 months). See all sponsors →

Open argenx on the live radar map → 📅 $ARGX readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
ADAPT SERON
NCT06298552
P3Active, not recruitingGeneralized Myasthenia Gravis; gMG1192025-06-30
VARVARA
NCT05907096
P2Active, not recruitingDelayed Graft Function1032025-10-16 (-5 mo)
ADAPT oculus
NCT06558279
P3Active, not recruitingMyasthenia Gravis, Ocular1412026-01-12 (+1 mo)
Empassion
NCT06742190
P3Active, not recruitingMultifocal Motor Neuropathy (MMN); MMN1542026-09
empacific
NCT06284954
P2Active, not recruitingDermatomyositis; Myositis32026-11 (+15 mo)
ADAPT Jr
NCT04833894
P2/3Active, not recruitingGeneralized Myasthenia Gravis152027-03 (+28 mo)
eSScape
NCT06655155
P2Active, not recruitingSystemic Sclerosis (SSc)872027-03 (+6 mo)
ADHERE+
NCT04280718
P2Active, not recruitingChronic Inflammatory Demyelinating Polyneuropathy (CIDP)2292027-04-30 (+35 mo)
Unity
NCT06684847
P3Active, not recruitingPrimary Sjogrens Disease6312027-07
emvigorate
NCT06920004
P3RecruitingChronic Inflammatory Demyelinating Polyneuropathy; CIDP2182027-09 (+4 mo)
ADAPT Jr SC
NCT06392386
P2/3RecruitingGeneralized Myasthenia Gravis122027-09 (+11 mo)
ADVANCE SC+
NCT04812925
P3Active, not recruitingPrimary Immune Thrombocytopenia1732027-10 (+12 mo)
ADAPT Forward2
NCT07673627
P2RecruitingAChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis (MG)402027-10
emnergize
NCT07091630
P3RecruitingChronic Inflammatory Demyelinating Polyneuropathy; CIDP1602027-10-07
Shamrock
NCT06503731
P2Active, not recruitingAntibody-mediated Rejection332027-11 (+2 mo)
embridge
NCT07821762
P2Not yet recruitingGuillain-Barré Syndrome (GBS)632028-01
Efgartigimod IV
NCT07284420
P2RecruitingAChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis702028-03-07
advance NEXT
NCT06544499
P3RecruitingPrimary Immune Thrombocytopenia (ITP)692028-06
VitaliThy
NCT07596849
P3RecruitingGraves Disease2302028-06
VitaliThy
NCT07570316
P3RecruitingGraves' Disease; Graves Disease2302028-06
SERENITY
NCT07760818
P2Not yet recruitingSjogrens Disease; Primary Sjögren's Syndrome Painful Sensory Neuropathies752028-07-28
ALKIVIA+
NCT05979441
P3Enrolling by invitationMyositis; Active Idiopathic Inflammatory Myopathy2402028-09 (+12 mo)
Advance Jr
NCT07194850
P2/3RecruitingImmune Thrombocytopenia (ITP); ITP - Immune Thrombocytopenia242028-10 (+7 mo)
Sparkle
NCT07287982
P2RecruitingSpinal Muscular Atrophy (SMA)602029-05-28
ADAPT Jr +
NCT05374590
P2/3Enrolling by invitationGeneralized Myasthenia Gravis; gMG122029-09 (+40 mo)
ARDA+
NCT05405361
P2Active, not recruitingMultifocal Motor Neuropathy (MMN)512029-09-30 (+47 mo)
Verdant
NCT07773727
P2RecruitingImmunoglobulin A Nephropathy (IgAN)1202029-10-29
Polaris
NCT07583641
P2Not yet recruitingAutoimmune Encephalitis (AE)1702030-07
CoMetS
NCT07746089
P3Not yet recruitingCongenital Myasthenic Syndrome; CMS1052030-10